Analytical Data
-
基因名
HDAC8
- Application
-
别名
RPD3; HDACL1; Histone Deacetylase-Like 1
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q9BY41
-
表达区间
Met1~Val377
-
分子量
46kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Histone deacetylase 8 (HDAC8) is a member of the class I histone deacetylases, which play a crucial role in the regulation of gene expression by removing acetyl groups from histone and non-histone proteins. It has gained significant attention in recent years due to its involvement in various cellular processes, including cell proliferation, differentiation, and apoptosis. Dysregulation of HDAC8 has been implicated in several diseases, particularly in cancer and neurodegenerative disorders. Its selective inhibition has emerged as a promising therapeutic strategy, restoring normal acetylation patterns and altering gene expression profiles. The recombinant production of HDAC8 is essential for understanding its structure, function, and interaction with inhibitors. By studying the enzyme's biochemical properties, researchers aim to elucidate its mechanisms of action and identify potential drug candidates targeting HDAC8. Additionally, the recombinant protein offers a platform for high-throughput screening of small molecules, facilitating the discovery of selective HDAC8 inhibitors. Overall, the research on HDAC8 and its recombinant protein is poised to contribute significantly to the development of innovative therapeutic approaches for diseases tied to its dysfunction.
